| Literature DB >> 34422903 |
Hanqing Hu1, Qian Zhang2, Rui Huang1, Zhifeng Gao3, Ziming Yuan1, Qingchao Tang1, Feng Gao1, Meng Wang2, Weiyuan Zhang1, Tianyi Ma1, Tianyu Qiao1, Yinghu Jin1, Guiyu Wang2.
Abstract
Background: The synchronous primary right-sided and left-sided colon cancer (sRL-CC) is a peculiar subtype of colorectal cancer. However, the genomic landscape of sRL-CC remains elusive.Entities:
Keywords: genome; heterogeneity; left-sided colon cancer; right-sided colon cancer; synchronous multiple primary cancer
Year: 2021 PMID: 34422903 PMCID: PMC8371635 DOI: 10.3389/fmolb.2021.689466
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
Demographic characteristic of the patients in our study.
| Age | Gender | CEA (ng/ml) | CA199 (U/ml) | Location | Histology | Differentiation | Stage | Perineural invasion | Venous invasion | Lymphatic invasion | |
| 1 | 60 | F | 6.58 | 146.26 | Right colon | TA/MA | Moderately | T3N1cM0 | Yes | Yes | Yes |
| Sigmoid colon | TA | Well/moderately | T1N0M0 | No | No | No | |||||
| 2 | 36 | F | 18.71 | 32.57 | Right colon | TA | Moderately | T3N0M0 | No | No | No |
| Sigmoid colon | TA | Moderately | T2N0M0 | No | No | No | |||||
| 3 | 84 | M | 3.15 | 17.26 | Right colon | TA/MA | Poorly | T3N1aM0 | No | Yes | Yes |
| Left colon | TA | Well | T2N0M0 | No | No | No | |||||
| 4 | 68 | M | 6.85 | 3.22 | Right colon | TA | Moderately | T3N0M0 | No | Yes | No |
| Sigmoid colon | TA | Moderately | T3N0M0 | Yes | Yes | No | |||||
| 5 | 70 | M | 10.34 | 16.39 | Right colon | VA | Moderately | T3N0M0 | Yes | No | Yes |
| Sigmoid colon | VA | Moderately | T1N0M0 | No | No | No | |||||
| 6 | 74 | F | 3.65 | 4.06 | Right colon | TA | Moderately | T3N0M0 | No | No | No |
| Sigmoid colon | TA | Moderately | T2N1aM0 | No | No | Yes | |||||
| 7 | 83 | M | 1.81 | 34.54 | Right colon | TA | Well | T1N0M0 | No | No | No |
| Sigmoid colon | TA | Well | T1N0M0 | No | No | No | |||||
| 8 | 45 | F | 1.37 | 11.06 | Right colon | TA/MA | Well/moderately | T2N0M0 | No | No | No |
| Left colon | TA | Well/moderately | T1N0M0 | No | No | No | |||||
| 9 | 75 | M | 49.83 | 31.53 | Right colon | TA | Moderately | T3N0M0 | No | No | No |
| Sigmoid colon | TA | Moderately | T3N0M0 | No | No | No | |||||
| 10 | 84 | M | 0.95 | 1.92 | Right colon | VA | Well/moderately | T2N0M0 | No | No | No |
| Sigmoid colon | TA | Moderately | T1N0M0 | No | No | No | |||||
| 11 | 58 | M | 28.36 | 79.83 | Right colon | TA | Moderately | T3N0M0 | Yes | Yes | Yes |
| Sigmoid colon | TA | Moderately | T2N0M0 | No | No | No | |||||
| 12 | 75 | M | 1.66 | 78.52 | Right colon | TA/MA | Moderately | T3N0M0 | No | No | No |
| Sigmoid colon | TA | Moderately | T1N0M0 | No | No | No | |||||
| 13 | 60 | M | 3.7 | 43.47 | Right colon | TA | Moderately | T3N0M0 | Yes | Yes | Yes |
| Sigmoid colon | TA | Moderately | T3N0M0 | Yes | No | No | |||||
| 14 | 50 | M | 24.08 | 8.98 | Right colon | MA | Poorly | T3N0M0 | Yes | No | No |
| Sigmoid colon | TA | Moderately | T1N0M0 | Yes | No | Yes |
F, female; M, male; TA, tubular adenocarcinoma; VA, villous adenocarcinoma; MA, mucinous adenocarcinoma.
FIGURE 1Single nucleotide variants analysis of sRL-CC. (A) Three SNV signatures are obtained from WES data in 14 sRL-CC patients. (B) Correlation analysis of three SNV signatures with known 30 signatures. The bar represents the coefficient index. (C) The box plot shows the percentage of the three signatures in left-sided and right-sided lesions when analyzed as a whole. Signature A: p = 0.722, two-tailed paired t test; signature B: p = 0.539, two-tailed paired t test; and signature C: p = 0.589, two-tailed paired t test. (D) The distribution of the three signatures in two lesions of each patient is presented by the heatmap.
FIGURE 2The mutational analysis of sRL-CC. (A) The frequent predisposing genes are presented by the heatmap. The tumor mutation burden is marked on the top of the heatmap, the name of predisposing genes is marked on the left, and the number of mutated samples is marked on the right. (B) The oncodriver gene mutations are presented by the heatmap. The tumor mutation burden is marked on the top of the heatmap, the name of predisposing genes is marked on the left, and the number of mutated samples is marked on the right. (C) The tumor mutation burden is calculated in the left-sided and right-sided lesions. (D) The tumor mutation burden is calculated in both lesions of each patient. (E) The significant mutated genes are presented by the heatmap. The tumor mutation burden is marked on the top of the heatmap.
FIGURE 3The copy number variants analysis of sRL-CC. (A) GISTIC analysis of left-sided and right-sided lesions. The G-score represents the degree of CNV amplification (upper panel) and deletion (lower panel). L-group means left-sided lesions and R-group means right-sided lesions. (B) The upper chart illustrates the distribution of copy number variants. Red presents the CNV gain, green presents normal CNV, and blue presents CNV loss. The lower chart illustrates the distribution of β allelic frequency (BAF). Orange means the normal distribution of allele and blue means loss of heterozygosity. (C) Circos plots illustrate the molecular landscape of genome in patients 2 and 4 in terms of copy number variants in each patient. The first circle means the depth of sequencing, the second circle means the density of SNP insert and deletion, and the third circle means the distribution of CNVs. In the third circle, red means the CNV gains, green means normal copy number, and blue means CNV loss.
FIGURE 4The clonal architecture and evolution analysis of sRL-CC. (A) The phylogenetic tress analysis of patients 1–6. The trunk represents the common mutations and the branch represents unique mutations in each lesion. The number of mutations is marked. (B) The scatter plot demonstrates cancer cell fraction (CCF) of the mutations in both lesions of patients 1–6. Different colors represent different clusters. The clusters located in the middle area of the plot mean shared clusters by both lesions, and those located near the X-axis and Y-axis mean unique clusters in each lesion.